Muutke küpsiste eelistusi

Brain Protection Strategies and Nanomedicine, Volume 266 [Kõva köide]

Volume editor (Secretary of Research, Uppsala University Hospital, Uppsala University, Sweden), Volume editor (Professor, Uppsala University, Sweden)
  • Formaat: Hardback, 416 pages, kõrgus x laius: 235x191 mm, kaal: 1000 g
  • Sari: Progress in Brain Research
  • Ilmumisaeg: 19-Oct-2021
  • Kirjastus: Elsevier - Health Sciences Division
  • ISBN-10: 0323989276
  • ISBN-13: 9780323989275
Teised raamatud teemal:
  • Kõva köide
  • Hind: 279,93 €*
  • * saadame teile pakkumise kasutatud raamatule, mille hind võib erineda kodulehel olevast hinnast
  • See raamat on trükist otsas, kuid me saadame teile pakkumise kasutatud raamatule.
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Lisa soovinimekirja
  • Formaat: Hardback, 416 pages, kõrgus x laius: 235x191 mm, kaal: 1000 g
  • Sari: Progress in Brain Research
  • Ilmumisaeg: 19-Oct-2021
  • Kirjastus: Elsevier - Health Sciences Division
  • ISBN-10: 0323989276
  • ISBN-13: 9780323989275
Teised raamatud teemal:

Brain Protection Strategies and Nanomedicine, Volume 266 in the Progress in Brain Research serial highlights new advances in the field, with this new volume presenting interesting chapters on a variety of topics, including Histamine H3 and H4 receptors modulate Parkinson’s disease induced brain pathology: Neuroprotective effects of nanowired BF-2649 and clobenpropit with anti-histamine-antibody therapy, Ultra Early Molecular Biologic Diagnosis Of Malignant And Neurodegenerative Diseases By The Immunospecific Profiles Of The Proteins Markers Of The Surface Of The Mobilized Autologous Hematopoietic Stem Cells, Neuroprotective effects of Insulin like growth factor-1 on Engineered metal Nanoparticles Ag, Cu and Al induced blood-brain barrier breakdown, and more.

Other chapters cover how Methamphetamine exacerbates pathophysiology of traumatic brain injury at high altitude: Neuroprotective effects of nanodelivery of a potent antioxidant compound H-290/51, Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation, and more.

  • Provides the authority and expertise of leading contributors from an international board of authors
  • Presents the latest release in Progress in Brain Research serials
  • Includes the latest information on brain protection strategies and nanomedicine

Arvustused

"This book specifically highlights recent scientific discoveries in the realm of brain protection strategies and nanomedicine. It brings together neuroscientists from all over the globe who detail cutting-edge clinical and pre-clinical neuroscientific research. By presenting these peer-reviewed chapters...the book showcases advances that help provide insight into how clinical research is conducted and how far scientific progress has taken us.... These are worthy objectives, and this book fits neatly into achieving these objectives in order to encourage further research in neuroscience and nanomedicine.... This book is a wonderful addition to those familiar with the current environment of neurosciences, neurological diseases, and biotechnology, who wish to explore further in development of novel neurotherapeutic agents using nanomedicine.... It is quite helpful to its intended audience of clinical and preclinical neuroscientists. It does justice to its purpose and is a worthy addition to any neuroscientists library." --Ali A Saherwala, MD(Thomas Jefferson University)

Contributors v
Acknowledgments xix
Preface xxi
Chapter 1 Histamine H3 and H4 receptors modulate Parkinson's disease induced brain pathology. Neuroprotective effects of nanowired BF-2649 and clobenpropit with anti-histamine-antibody therapy 1(74)
Aruna Sharma
Dafin F. Muresanu
Ranjana Patnaik
Preeti K. Menon
Z. Ryan Tian
Seaab Sahib
Rudy J. Castellani
Ala Nozari
Jose Vicente Lafuente
Anca D. Buzoianu
Stephen D. Skaper
Igor Bryukhovetskiy
Igor Manzhulo
Lars Wiklund
Hari Shanker Sharma
1 Introduction
2(6)
1.1 Histaminergic system in the brain
4(1)
1.2 Histaminergic receptors in the brain
5(1)
1.3 Histamine in brain diseases
5(3)
2 Histaminergic system alterations in Parkinson's disease
8(2)
2.1 Histamine concentration in PD
8(1)
2.2 Histaminergic nerve fibers in PD
8(1)
2.3 Histaminergic gene and receptors in PD
9(1)
3 Our own investigations on histamine modulation of Parkinson's disease
10(7)
3.1 Methodological consideration
10(1)
3.2 Animal model of PD
10(1)
3.3 Modulation of histaminergic agents
10(1)
3.4 Parameters measured
11(3)
3.5 Behavioral functions
14(1)
3.6 Biochemical measurements
15(1)
3.7 Neuropathology of Parkinson's disease
15(2)
4 Results
17(19)
4.1 MPTP induced PD mouse model
17(11)
4.2 Blood-brain barrier disturbances in PD
28(1)
4.3 Cerebral blood flow in PD
28(1)
4.4 Brain edema and volume swelling in PD
28(2)
4.5 Brain pathology in PD
30(6)
5 Histamine modulating agent's for neuroprotection in PD
36(8)
5.1 Histamine H3 receptor inverse agonist BF2649
36(2)
5.2 Histamine H3 receptor antagonist and partial H4 receptor agonist clobenpropit
38(2)
5.3 Nanowired delivery of histaminergic agents
40(4)
6 Discussion
44(4)
6.1 Conclusion and future perspective
47(1)
Acknowledgments
48(1)
Conflict of interest
48(1)
References
48(27)
Chapter 2 Ultra early molecular biologic diagnosis of malignant and neurodegenerative diseases by the immunospecific profiles of the proteins markers of the surface of the mobilized autologous hematopoietic stem cells 75(22)
Andrey S. Bryukhovetskiy
Lyudmila Y. Grivtsova
Hari Shanker Sharma
1 Introduction
76(3)
2 Materials and methods
79(3)
3 Results
82(5)
4 Discussion
87(6)
5 Conclusion
93(1)
Conflict of interests
94(1)
References
94(3)
Chapter 3 Neuroprotective effects of insulin like growth factor-1 on engineered metal nanoparticles Ag, Cu and Al induced blood-brain barrier breakdown, edema formation, oxidative stress, upregulation of neuronal nitric oxide synthase and brain pathology 97(26)
Hari Shanker Sharma
Jose Vicente Lafuente
Dafin F. Muresanu
Seaab Sahib
Z. Ryan Tian
Preeti K. Menon
Rudy J. Castellani
Ala Nozari
Anca D. Buzoianu
Per-Ove SjOquist
Ranjana Patnaik
Lars Wiklund
Aruna Sharma
1 Introduction
98(2)
2 Materials and methods
100(2)
2.1 Animals
100(1)
2.2 Administration of nanoparticles
100(1)
2.3 Insulin like growth factor-1 (IGF-1) administration
100(1)
2.4 Measurement of oxidative stress parameters in the brain
100(1)
2.5 Blood-brain barrier and neuronal injury
101(1)
2.6 Brain edema formation
101(1)
2.7 Morphological analysis
101(1)
2.8 Nitric oxide activity
101(1)
2.9 Statistical analyses of data
102(1)
3 Results
102(7)
3.1 Nanoparticles intoxication induces oxidative stress
102(2)
3.2 Nanoparticles intoxication induces BBB disruption
104(1)
3.3 Nanoparticles intoxication induces brain edema
104(1)
3.4 Nanoparticles intoxication induces neuronal nitric oxide synthase upregulation
104(1)
3.5 Nanoparticles intoxication induces neuronal injuries
104(3)
3.6 Effect of insulin like growth factor-1 (IGF-1) on nanoneurotoxicity
107(2)
4 Discussion
109(1)
Acknowledgments
110(1)
Conflict of interest
111(1)
References
111(12)
Chapter 4 Methamphetamine exacerbates pathophysiology of traumatic brain injury at high altitude. Neuroprotective effects of nanodelivery of a potent antioxidant compound H-290/51 123(72)
Hari Shanker Sharma
Jose Vicente Lafuente
Lianyuan Feng
Dafin F. Muresanu
Preeti K. Menon
Rudy J. Castellani
Ala Nozari
Seaab Sahib
Z. Ryan Tian
Anca D. Buzoianu
Per-Ove Sjoquist
Ranjana Patnaik
Lars Wiklund
Aruna Sharma
1 Introduction
124(6)
1.1 Brain function at high altitude
126(4)
2 Methamphetamine at high altitude
130(3)
2.1 History of methamphetamine
130(3)
3 Traumatic brain injury at high altitude
133(2)
3.1 Secondary brain injury processes are affected at high altitude
134(1)
4 Our observation on methamphetamine and traumatic brain injury at high altitude
135(6)
4.1 Methodological consideration
135(1)
4.2 Concussive head injury
136(1)
4.3 Pathophysiology of brain injury
137(2)
4.4 Brain pathology
139(2)
4.5 Statistical analysis
141(1)
5 Results
141(8)
5.1 Physiological parameters at normobaric control group
141(5)
5.2 Blood-brain barrier permeability in normobaric group
146(2)
5.3 Cerebral blood flow in control at normobaric group
148(1)
5.4 Brain edema and volume swelling in control at normobaric group
148(1)
6 Biochemical changes
149(2)
6.1 Beta catenin level at normobaric group
149(2)
7 Brain pathology
151(2)
7.1 Neuronal injury at normobaric group
151(2)
8 Glial fibrillary acidic protein immunoreactivity
153(1)
8.1 GFAP reactivity in control at normobaric group
153(1)
9 Myelin damage of control at normobaric group
154(2)
9.1 Myelin damage in CHI at normobaric group
154(1)
9.2 Myelin damage at high altitude group
154(2)
9.3 Myelin damage in CHI at high altitude group
156(1)
10 Endothelial distortion at normobaric group
156(1)
10.1 Endothelial distortion in CHI at normobaric group
156(1)
10.2 Endothelial distortion at high altitude group
156(1)
10.3 Endothelial distortion in CHI at high altitude group
156(1)
11 Treatment with antioxidant drug H-290/51
157(3)
11.1 Treatment with nanowired H-290/51
158(2)
12 Discussion
160(3)
13 Future perspectives
163(1)
Acknowledgment
164(1)
Conflict of interest
164(1)
References
164(31)
Chapter 5 Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation 195(16)
Oleg Pak
Sergei Zaitsev
Valery Shevchenko
Aruna Sharma
Hari Shanker Sharma
Igor Bryukhovetskiy
1 Introduction
196(1)
2 Materials and methods
197(2)
2.1 Human glioblastoma cells
197(1)
2.2 Recurrent GBM model
197(1)
2.3 Proteomics-based comparative mapping of GBM cells
197(1)
2.4 Used chemicals
198(1)
2.5 Pharmaceutical agents
198(1)
2.6 Method of in vitro testing
198(1)
2.7 Flow cytometry
198(1)
3 Results
199(4)
3.1 Characteristics of T98G line of GBM cells after radiation treatment
199(1)
3.2 Proteomics-based comparative mapping of T98G line cell of GBM after radiation treatment
199(1)
3.3 Testing the effect of cytotoxic and targeted agents on an in vitro model of recurrent GBM
200(3)
4 Discussion
203(3)
Funding
206(1)
Ethics approval and consent to participate
206(1)
Authors' contributions
207(1)
Conflict of interest
207(1)
References
207(4)
Chapter 6 Cerebrolysin restores balance between excitatory and inhibitory amino acids in brain following concussive head injury. Superior neuroprotective effects of TiO2 nanowired drug delivery 211(58)
Hari Shanker Sharma
Dafin F. Muresanu
Seaab Sahib
Z. Ryan Tian
Jose Vicente Lafuente
Anca D. Buzoianu
Rudy J. Castellani
Ala Nozari
Cong Li
Zhiquiang Zhang
Lars Wiklund
Aruna Sharma
1 Introduction
212(2)
2 Materials and methods
214(8)
2.1 Animals
214(1)
2.2 Control group
215(1)
2.3 Survival periods
215(1)
2.4 Cerebrolysin treatment
215(2)
2.5 TiO2 nanowired cerebrolysin delivery
217(1)
2.6 Parameters measured
217(1)
2.7 Blood-brain barrier permeability
217(1)
2.8 Brain edema formation
218(1)
2.9 Neuropathology
219(1)
2.10 Measurement of amino acid neurotransmitters
220(1)
2.11 Physiological variables
220(1)
2.12 Behavioral parameters
221(1)
3 Results
222(22)
3.1 Physiological variables
222(1)
3.2 Behavioral symptoms
222(3)
3.3 Excitatory amino acids aspartate and glutamate
225(1)
3.4 Inhibitory amino acids glycine and GABA
225(5)
3.5 Blood-brain barrier permeability
230(1)
3.6 Brain edema formation
230(9)
3.7 Brain pathology
239(1)
3.8 Effect of cerebrolysin in concussive head injury
240(1)
3.9 Physiological variables
241(1)
3.10 Behavioral function
241(1)
3.11 Excitatory amino acids in brain
242(1)
3.12 Inhibitory amino acids
242(1)
3.13 Blood-brain barrier
242(1)
3.14 Brain edema
242(1)
3.15 Brain pathology
243(1)
3.16 Nanodelivery of cerebrolysin
243(1)
4 Discussion
244(4)
Acknowledgment
248(1)
Conflict of interest
249(1)
References
249(20)
Chapter 7 Neuromodulation as a basic platform for neuroprotection and repair after spinal cord injury 269(32)
Artur Biktimirov
Oleg Pak
Igor Bryukhovetskiy
Aruna Sharma
Hari Shanker Sharma
1 Introduction
270(1)
2 Pathophysiology of SC injury and regeneration
271(2)
3 Strategy for treating SCI patients: Reanimation, neuroprotection and blood-brain barrier
273(1)
4 Spasticity
274(4)
5 Surgical treatment of spasticity
278(5)
5.1 Intrathecal baclofen therapy (ITB)
278(3)
5.2 Spinal cord stimulation (SCS)
281(2)
6 Biomedical technologies in SCI treatment
283(3)
7 Prospects of integrating biomedical and bionic technologies
286(2)
8 Conclusion
288(2)
Acknowledgments
290(1)
Authors' contributions
290(1)
Patient consent for publication
290(1)
Competing interests
290(1)
References
290(11)
Chapter 8 Superior antioxidant and anti-ischemic neuroprotective effects of cerebrolysin in heat stroke following intoxication of engineered metal Ag and Cu nanoparticles: A comparative biochemical and physiological study with other stroke therapies 301(48)
Hari Shanker Sharma
Dafin F. Muresanu
Asya Ozkizilcik
Seaab Sahib
Z. Ryan Tian
Josi Vicente Lafuente
Rudy J. Castellani
Ala Nozari
Lianyuan Feng
Anca D. Buzoianu
Preeti K. Menon
Ranjana Patnaik
Lars Wiklund
Aruna Sharma
1 Introduction
303(1)
2 Materials and methods
304(7)
2.1 Animals
304(1)
2.2 Exposure to heat stress
304(1)
2.3 Nanoparticles exposure
305(1)
2.4 Drug treatments
305(1)
2.5 Nanowired delivery of cerebrolysin (NWCBL)
306(1)
2.6 Parameters measured
306(1)
2.7 Stress symptoms
306(1)
2.8 Physiological variables
307(1)
2.9 Blood-brain barrier breakdown
307(1)
2.10 Cerebral blood flow
308(1)
2.11 Brain edema and volume swelling (%f)
308(1)
2.12 Oxidative stress parameters
309(1)
2.13 Brain pathology
310(1)
2.14 Statistical analyses of the data obtained
311(1)
3 Results
311(22)
3.1 Effect of heat stroke on stress symptoms
311(1)
3.2 Physiological variables
311(4)
3.3 Blood-brain barrier breakdown
315(1)
3.4 Brain edema
315(3)
3.5 Cerebral blood flow
318(1)
3.6 Oxidative stress parameters
318(1)
3.7 Brain pathology
318(12)
3.8 Effect of drug treatments on nanoparticles intoxication in heat stroke
330(3)
4 Discussion
333(4)
Acknowledgments
337(1)
Conflict of interests
337(1)
References
337(12)
Chapter 9 A clinical study of high-dose urokinase for the treatment of the patients with hypertension induced ventricular hemorrhage 349(8)
Chao He
Gang Yang
Ming Zhao
Qilin Wu
Lin Wang
Hari Shanker Sharma
1 Data and methods
350(2)
1.1 General data
350(1)
1.2 Inclusion criteria
351(1)
1.3 Exclusion criteria
351(1)
1.4 Therapy
351(1)
1.5 Extubation indicators
352(1)
1.6 Assessment of therapeutic effect
352(1)
1.7 Statistical method
352(1)
2 Results
352(1)
3 Discussion
353(2)
Funding
355(1)
References
355(2)
Chapter 10 Topical application of CNTF, GDNF and BDNF in combination attenuates blood-spinal cord barrier permeability, edema formation, hemeoxygenase-2 upregulation, and cord pathology 357(20)
Aruna Sharma
Lianyuan Feng
Dafin F. Muresanu
Hongyun Huang
Preeti K. Menon
Seaab Sahib
Z. Ryan Tian
Jose Vicente Lafuente
Anca D. Buzoianu
Rudy J. Castellani
Ala Nozari
Lars Wiklund
Hari Shanker Sharma
1 Introduction
358(1)
2 Materials and methods
359(2)
2.1 Animals
359(1)
2.2 Spinal cord injury
359(1)
2.3 Neurotrophins treatment
360(1)
2.4 Morphological investigations of the spinal cord
360(1)
2.5 Hemeoxygenase 2 immunostaining of the spinal cord
360(1)
2.6 Cell injury in the spinal cord
360(1)
2.7 Blood-spinal cord barrier permeability
361(1)
2.8 Spinal cord edema
361(1)
2.9 Spinal cord blood flow
361(1)
2.10 Statistical analyses of the data
361(1)
3 Results
361(7)
3.1 Effect of neurotrophins on HO-2 expression in the cord after trauma
361(3)
3.2 Effect of neurotrophins on neuronal injury in the cord after trauma
364(1)
3.3 Effect of neurotrophins on blood-spinal cord barrier permeability after trauma
365(1)
3.4 Effect of neurotrophins on spinal cord edema after trauma
366(1)
3.5 Effect of neurotrophins on spinal cord blood flow after trauma
367(1)
4 Discussion
368(2)
Acknowledgments
370(1)
Conflict of interest
371(1)
References
371(6)
Chapter 11 Diagnosis experience and literature review of patients with cervical, thoracic and lumbar multi-segment spinal stenosis: A case report 377
Chao He
Xu Longbiao
Ming Zhao
Lin Wang
Hari Shanker Sharma
1 Background
378(1)
2 Case presentation
378(3)
3 Discussion
381(2)
4 Conclusion
383(1)
Funding
383(1)
References
383
Dr. Hari Shanker Sharma, Professor of Neurobiology (MRC), Docent in Neuroanatomy (UU) is currently working in Uppsala University Hospital, Department of Surgical Sciences, Division of Anesthesiology & Intensive Care Medicine, Uppsala University, Sweden. Dr Sharma obtained his Masters Degree from Bihar University with special expertise in Cell Biology in 1976 and was awarded the Gold Medal of Bihar University for securing 1st position in the 1st Class. Dr Sharma joined the group of Professor Prasanta Kumar Dey, a neurophysiologist, by training in the Department of Physiology, Institute of Medical; Sciences, Banaras Hindu University, Varanasi in 1977 to obtain his Doctor of Philosophy Degree (D.Phil.) in Neurosciences and was awarded his Ph.D. in 1982 on Blood-Brain Barrier in Stress.” After carrying out a series of Government of India funded Research Projects on the BBB and brain dysfunction (19821987), Dr Sharma joined the lab of Neuropathology at Uppsala University with Professor Yngve Olsson in 1988 to investigate passage of tracer transport across the BBB caused by stress or traumatic insults to the Brain and Spinal cord at light and electron microscopy. Dr Sharma was awarded the prestigious Alexander von Humboldt Foundation Fellowship of German Government (19891991) to work on hyperthermia induced BBB dysfunction at the ultrastructural level in the laboratory of Professor Jorge Cervós-Navarro (a living Legend in Neuropathology in Europe”). Dr Sharma again joined Uppsala University and established a network of collaboration on Experimental CNS Injury Research Group” as a lead investigator with eminent collaborators in various parts of Europe, USA, and Australia (1991). On his work on hyperthermia Dr Sharma received the prestigious Neuroanatomy award Rönnows Research prize” of Uppsala University for best neuroanatomical research of the year 1996” followed by the Award of the Degree of Doctor of Medical Sciences of Uppsala University in Neuroanatomy in 1999 and selected for the Best Thesis Award of the Medical faculty, The Hwassers Prize” of 1999. On his meticulous works on the Blood Brain barrier and Brain edema (20002003) Dr. Sharma earned the prestigious title of Docent in Neuroanatomy” of Medical Faculty, Uppsala University in April 2004. Currently his main research interest is Neuroprotection and Neuroregeneration, in relation to the Blood-brain barrier in stress, trauma, and drugs of abuse in health and disease. Dr. Sharma on his research on brain pathology and neuroprotection in different models received the prestigious award from The Laerdal Foundation of Acute Medicine, Stavanger, Norway, in 2005 followed by Distinguished International Scientists Collaboration Award by National Institute on Drug Abuse (NIDA), Baltimore, MD (20062008). His recent work on 5-HT3 receptor mediated neuroprotection in morphine withdrawal induced neurotoxicity won the coveted prize of Best Investigator Award 2008 and Best Scientific Presentation by European Federation of the International Association for Study of Pain (ISAP), and Awarded during their VI Annual Meeting in Lisbon, September 912, 2008. His recent research is aimed to find out the role of nanoparticles in Neurodegeneration and Neuroprotection using various treatment strategies that is supported by European Aerospace Research and Development (EOARD), London, UK and US Air Force Research Laboratory, Wright Patterson Air Force Base, Dayton, Oh, USA. On his works on Bloodbrain barrier in hypertension and diabetes together with Romanian colleagues, University of Medicine and Pharmacy Iuliu Hatieganu,” Cluj-Napoca, Romania awarded Dr. Sharma with Honorary Doctorate of Medical Sciences in 2009. Dr Sharmas work over 30 years on the blood-brain barrier and brain edema won him the US Neurosurgeon Dr Anthony Marmarou Award (2011) by the International Brain Edema Society at their 15th Congress in Tokyo, Japan, November 2011. His works on Nanoneuroscience and development of nanomedicine to treat the CNS injuries has won accolades at various Government and International Scotties or Organization across the World. Accordingly Dr Sharma was decorated with the most prestigious ”Hind Rattan Award 2012” on the eve of Republic Day of India in January 2012 and Mahatma Gandhi Pravasi Gold Medal in October 2012 in House of Lords, London, UK. Dr Sharma was also invited to organize and chair Nanosymposium in Society for Neuroscience meetings in Chicago (2009), San Diego (2010), Washington DC (2011) and New Orleans (2012). Dr Sharma has published over 380 research papers, 75 reviews, 12 monographs, and 70 international book chapters and edited 15 book volumes. Aruna Sharma, MD is currently Secretary of Research at Uppsala University Hospital, Uppsala University, Sweden. She obtained her Bachelor of Science in 1971 and trained in Indian Medicine up to 1977 and engaged in medical research from 1978 to 1986 in India on hyperthermia induced brain dysfunction in the lab of Hari Sharma and Prasanta Kumar Dey under University Grants Commission and Indian Council of Medical Research

Her main interest is now focused on Indian Medicinal drugs and their effects on the Central Nervous System Function, toxicology, neurorepair and neuroprotection. She is also investigating neurotoxicological profiles of many Ayurvedic traditional drugs with special reference to those containing metal oxide or metal ashes.